Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors return for Spiration's seventh round

Executive Summary

Spiration (minimally invasive devices for respiratory diseases) closed an $18.5mm Series G financing from existing shareholders. Lead investor Versant Ventures was joined by Olympus Medical Systems, New Enterprise Associates, New Leaf Venture Partners, InterWest Partners, Investor Growth Capital, and Three Arch Partners. The company will use the funds to complete the clinical testing needed to get its IBV airflow redirection system approved in the US for emphysema; the product already holds the CE Mark in Europe. The Series G money now brings the total invested in Spiration up to $97mm.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies